Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SC10914 in Advanced Solid Tumors
NCT02940132Phase 1Unknown
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Start
- Oct 2016
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SC10914 in solid tumor (advanced stage), sponsored by Jiangxi Qingfeng Pharmaceutical Co. Ltd. Primary endpoints: Maximum-tolerated Dose at 30 days and Recommended Phase II Dose at 8 weeks. Status: unknown.
02
Drugs
SC10914
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02940132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02940132.